Risks of Advair (Fluticasone/Salmeterol) Use in Patients Without Documented Asthma or COPD

Cardiovascular Adverse Effects of the Long‑Acting β₂‑Agonist

The salmeterol component can precipitate cardiovascular adverse events such as tachycardia, palpitations, and an overall increase in cardiovascular events in patients receiving the drug without a proper indication. Evidence level: not specified. 1

Inhaled fluticasone is associated with oropharyngeal candidiasis, dysphonia, easy bruisability, and, in patients with COPD, an approximately 4 % higher incidence of pneumonia compared with non‑users. Evidence level: not specified. 2

Advair is intended to improve clinical outcomes only in individuals with documented asthma (confirmed by spirometry and clinical criteria) or COPD with demonstrable airflow limitation; benefits have not been shown in patients lacking these obstructive airway diseases. Evidence level: not specified. [1][2]

Clinicians should not prescribe Advair empirically for unexplained shortness of breath; a definitive diagnosis of asthma or COPD must be established first using appropriate testing (e.g., spirometry with bronchodilator response). Evidence level: not specified. 1

When a patient without obstructive airway disease is already receiving Advair, the medication should be discontinued, and a thorough diagnostic work‑up for the underlying cause of dyspnea should be undertaken. Evidence level: not specified. [1][2]

The fixed‑dose combination of inhaled corticosteroid (fluticasone propionate) and long‑acting β₂‑agonist (salmeterol) is recommended as step 3 or higher therapy for patients with moderate‑to‑severe persistent asthma, favoring the combination over simply increasing the inhaled corticosteroid dose【3】【4】.
Long‑acting β₂‑agonists must never be prescribed as monotherapy for asthma; they should always be paired with an inhaled corticosteroid because monotherapy is associated with a higher risk of severe exacerbations and asthma‑related mortality【3】【5】.

In patients with chronic obstructive pulmonary disease, the fluticasone/salmeterol combination is associated with an approximately 4 % higher incidence of pneumonia compared with treatment using a long‑acting β₂‑agonist alone【6】.